USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
The Next Generation of Cancer Therapies
19-Jan-2018
North America
Market Research
MC55-01-00-00-00
HC02963-NA-MR_21491
Immuno-oncology refers to drugs that are used to stimulate the human immune system to target the fight against cancer. The immune system is capable of recognizing and eliminating foreign substances, including tumor cells. Tumors have, however, been able to escape detection by the immune system. There are drugs that can empower the immune system cells to attack tumor cells. Natural Killer (NK) cells are the main cells involved in the natural immune response. Once an immune response is initiated, the immune response can be sustained through memory, called adaptive immunity. Cytotoxic T cells are the main cells involved with adaptive immunity. The anti-cancer activity of NK cells and cytotoxic T cells is done through activating and inhibiting signal pathways.
Chimeric antigen receptor (CAR) T-cell therapy will change the way cancer is being treated. In the second half of 2017, the first two drugs in this new class of therapy were approved. Autologous T-cells that have been re-engineered can resist the immunosuppressive effects of tumors. The approved CAR-T therapies are directed against CD19 antigens and are approved to treat B-cell lymphoma and acute lymphocytic leukemia’s, both B-cell mediated diseases. The process involved engineering autologous antigen presenting cells removed from the patient and run through a manufacturing process that takes 17 to 29 days depending on the drug before being infused back into the patient. There are over 200 clinical trials underway with CAR-T therapeutics, some trials in combination with already approved checkpoint inhibitors. The autologous therapies are patient-specific personalized treatments. The costs are staggering for these therapies, with treatments for the drug alone costing hundreds of thousands of dollars. That does not include the costs for other chemotherapies, hospital inpatient, and ICU care costs. Hospitals and clinics running the trials have experienced doctors and nurses that know how to handle this therapy. Expanding to new treatment arenas will be a challenge.
Research advances in combination trials targeting more than one pathway may increase response rates over single targeted agents. If a combination product is produced by one company, it could be priced more competitively than targeted agents developed and marketed through a competitors’ alliance.
New approaches to adoptive T-cell therapies remain a hurdle, but the ultimate goals of increasing overall survival are not insurmountable. Changes in standards-of-care may limit access to patients for clinical trials for these new therapies.
Key Issues Addressed
- What adoptive T-cell (CAR-T & TCR) therapies are in development and for what indications?
- What products and indications will be launched in the next 7 years?
- Who is investing in the development of adoptive T-cell therapies, at what phase, and at what level of deal funding?
- What are some of the cost implications for adoptive T-cell therapies, especially when combined with other immuno-oncology therapies?
- What are the challenges to development and commercialization of adoptive T-cell therapies?
- What challenges do payors face related to the high cost of specialty therapeutics?
Key Takeaway
Scope and Segmentation
Key Questions this Study will Answer
Executive Summary—Market Snapshot
Executive Summary—Market Snapshot (continued)
8 Big Market Themes for Immuno-oncology Therapies
Hematological Cancers Dominate the Pipeline
Game Changing Companies
Investors Pour in Significant Funds
Key 2017 Predictions—Adoptive T-cell Therapy Market
Key Methodology
Adoptive T-cell Therapy Drug Classes
Timeline of Adoptive T-cell Product Evolution
Timeline of Adoptive Immuno-oncology Product Approvals
Competitive Landscape—Target Segments
Competitive Landscape—Target Product Counts
Adoptive T-cell Therapy Segmentation
Competitive Landscape—CAR-T (Chimeric Antigen Receptor T-cells)
Competitive Landscape—CAR-T (Chimeric Antigen Receptor T-cells) (continued)
Competitive Landscape—CAR-T (Chimeric Antigen Receptor T-cells) CR
Competitive Landscape—T-cell Receptor (TCR) Segment
CAR-T Product Dashboard
CAR-T Product Dashboard (continued)
TCR Product Dashboard
Opportunities in this Market
Challenges for this Market
Potential Game Changing Immuno-oncology Therapies
Overall Environmental Impact Factors
Immuno-oncology Area Product Patent Expirations
Antigen Targets
Opportunities in this Market—Escalating Drug Costs
Adoptive T-cell Therapy Payor Environment
J-Codes, Annual Costs and US Payors
Adoptive T-cell Therapies—On-Label Reimbursement Path
Reimbursement Pathway—Off-Label: Medicare
Reimbursement Pathway—Off-Label: Commercial Payors
Reimbursement Pathway—Off-Label: Commercial Payors (continued)
A Snapshot of Global Drug Price Control Methods
Pitfalls to Avoid
Companies to Watch
Companies to Watch (continued)
Adoptive T-cell Therapy Forecast—2022 ($3.9 Billion) Forecasts by Product
Immuno-oncology Milestones
Immuno-oncology Milestones (continued)
Deal and Financing—Adoptive T-cell Therapies
Deal and Financing—Adoptive T-cell Therapies (continued)
Deal and Financing—Adoptive T-cell Therapies (continued)
Deal and Financing—Adoptive T-cell Therapies (continued)
Deal and Financing—Adoptive T-cell Therapies (continued)
Deal and Financing—Adoptive T-cell Therapies (continued)
Deal and Financing—Adoptive T-cell Therapies (continued)
Deal and Financing—Adoptive T-cell Therapies (continued)
Deal and Financing—Adoptive T-cell Therapies (continued)
Deal and Financing—Adoptive T-cell Therapies (continued)
Deal and Financing—Adoptive T-cell Therapies (continued)
Deal and Financing—Adoptive T-cell Therapies (continued)
Deal and Financing—Adoptive T-cell Therapies (continued)
Deal and Financing—Adoptive T-cell Therapies (continued)
Deal and Financing—Adoptive T-cell Therapies (continued)
Deal and Financing—Adoptive T-cell Therapies (continued)
Deal and Financing—Adoptive T-cell Therapies (continued)
Key Conclusions
New Market Opportunities—Adoptive T-cell Therapies
The Last Word—3 Big Predictions
Legal Disclaimer
Pipeline Analysis—CAR-T Segment, Products in Development
Pipeline Analysis—CAR-T Segment, Products in Development (continued)
Pipeline Analysis—CAR-T Segment, Products in Development (continued)
Pipeline Analysis—CAR-T Segment, Products in Development (continued)
Pipeline Analysis—CAR-T Segment, Products in Development (continued)
Pipeline Analysis—CAR-T Segment, Products in Development (continued)
Pipeline Analysis—CAR-T Segment, Products in Development (continued)
Pipeline Analysis—CAR-T Segment, Products in Development (continued)
Pipeline Analysis—CAR-T Segment, Products in Development (continued)
Pipeline Analysis—CAR-T Segment, Products in Development (continued)
Pipeline Analysis—CAR-T Segment, Products in Development (continued)
Pipeline Analysis—CAR-T Segment, Products in Development (continued)
Pipeline Analysis—CAR-T Segment, Products in Development (continued)
Pipeline Analysis—CAR-T Segment, Products in Development (continued)
Pipeline Analysis—CAR-T Segment, Products in Development (continued)
Pipeline Analysis—CAR-T Segment, Products in Development (continued)
Pipeline Analysis—CAR-T Segment, Products in Development (continued)
Pipeline Analysis—CAR-T Segment, Products in Development (continued)
Pipeline Analysis—CAR-T Segment, Products in Development (continued)
Pipeline Analysis—CAR-T Segment, Products in Development (continued)
Pipeline Analysis—CAR-T Segment, Products in Development (continued)
Pipeline Analysis—T-cell Receptor Segment, Products in Development
Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)
Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)
Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)
Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)
Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)
Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)
Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)
Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)
List of Exhibits
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
The Frost & Sullivan Story
Value Proposition—Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Speak directly with our analytics experts for tailored recommendations.
Recent related Healthcare research
15 Sep 2026 | Global | Market Research
Vendor Profiles: Advanced Wound Care Management Market, Global, 2025
The wound care market is being transformed by advanced technologies and evolving care models that focus on improving patient outcomes and reducing healthcare costs. Innovations such as smart sensor-embedded dressings, artificial intelligence (AI)-based wound imaging systems, enhanced negative pressu...
11 Sep 2026 | Global | Frost Radar
Frost Radar™: Pharmaceutical Commercialization Solutions and Services, 2026
Pharmaceutical commercialization is a multidimensional concept in the successful launch and distribution of a drug. The process includes the development of a pricing strategy that reflects the drug’s value, negotiation with payers to ensure drug cost coverage, regulatory compliance, and the generati...
07 Sep 2026 | Global | Technology Research
Synthetic Antibodies and AI-Optimized Immunotherapies
Artificial intelligence is becoming increasingly relevant to antibody discovery and immunotherapy development, supporting target identification, de novo antibody design, antibody engineering, clinical intelligence, and bioprocessing. Advances in generative AI, protein language models, diffusion mode...
28 Aug 2026 | Global | Technology Research
Innovations and Growth Opportunities in Advanced Medical Devices, Artificial Intelligence Solutions, Digital Solutions, and Medical Imaging Solutions
The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across advanced medical devices, artificial intelligence solutions, digital solutions, and medical imaging solutions.The issue features advanced medical devices such as active bioelectr...
27 Aug 2026 | Global | Frost Radar
Frost Radar: AI-Powered Molecular Diagnostics, 2026
AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, present...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Lightbox Content | World Cancer Day 2019|Get 15% discount for all Healthcare studies |https://store.frost.com/contacts/?utm_source=PD&utm_medium=lightbox&utm_campaign=HEALTHCARE_CANCER2019 |
| Author | Barbara Gilmore |
| Industries | Healthcare |
| WIP Number | MC55-01-00-00-00 |
| Is Prebook | No |
| GPS Codes | 9562-B1,9568-B1,9571-B1,9573-B1,9600-B1,9611-B1,9627-B1,99BF-B1,99C1-B1,99C6-B1,9A41-B1,9A42-B1,9A43-B1,9A44-B1,9A4E-B1,9A50-B1 |
The Global Immuno-oncology Therapeutics Market—Adoptive T-cell Therapies, Forecast to 2022
$3,000.00
Special Price $2,250.00 save 25 %